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Background
The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the 
efficacy of anthracyclines in the adjuvant treatment of early breast cancer.
Methods
In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophos-
phamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the 
BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, 
with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-
free and overall survival. The secondary end points were adverse effects, dose intensity, 
and quality of life.
Results
The two trials included 2391 women with early breast cancer; the median follow-up 
was 48 months. Relapse-free and overall survival rates were significantly higher in the 
epirubicin–CMF groups than in the CMF-alone groups (2-year relapse-free survival, 
91% vs. 85%; 5-year relapse-free survival, 76% vs. 69%; 2-year overall survival, 95% vs. 
92%; 5-year overall survival, 82% vs. 75%; P<0.001 by the log-rank test for all com-
parisons). Hazard ratios for relapse (or death without relapse) (0.69; 95% confidence 
interval [CI], 0.58 to 0.82; P<0.001) and death from any cause (0.67; 95% CI, 0.55 to 
0.82; P<0.001) favored epirubicin plus CMF over CMF alone. Independent prognostic 
factors were nodal status, tumor grade, tumor size, and estrogen-receptor status 
(P<0.001 for all four factors) and the presence or absence of vascular or lymphatic 
invasion (P = 0.01). These factors did not significantly interact with the effect of epi-
rubicin plus CMF. The overall incidence of adverse effects was significantly higher 
with epirubicin plus CMF than with CMF alone but did not significantly affect the 
delivered-dose intensity or the quality of life.
Conclusions
Epirubicin plus CMF is superior to CMF alone as adjuvant treatment for early breast 
cancer. (ClinicalTrials.gov number, NCT00003577.)
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The national epirubicin adjuvant Trial (NEAT) and the BR9601 trial were de-signed jointly by English and Scottish inves-
tigators in 1994 and 1995 to determine the value 
of anthracyclines in the adjuvant treatment of ear-
ly breast cancer. At that time, a combination of cy-
clophosphamide, methotrexate, and fluorouracil 
was standard treatment for early breast cancer in 
the United Kingdom. The role of anthracyclines 
had not been addressed in the 1990 Oxford Over-
view of the treatment of early breast cancer,1 and 
despite the activity of anthracyclines in metastat-
ic disease,2 data from adjuvant trials were incon-
sistent. Concerns about adverse effects and effects 
on the quality of life also delayed the inclusion of 
anthracyclines in adjuvant chemotherapy combi-
nations.
In 1991, the importance of scheduling the ad-
ministration of anthracyclines became evident. 
Studies in Milan3 showed that a block-sequential 
schedule of four cycles of doxorubicin at a dose of 
75 mg per square meter of body-surface area ev-
ery 3 weeks, followed by eight cycles of CMF every 
3 weeks, was superior to a 2:1 alternating regimen 
of the same drugs, at the same cumulative doses 
during the same period.4,5 A companion study 
failed to show the superiority of 8 cycles of CMF 
followed by 4 cycles of doxorubicin over 12 cycles 
of CMF.6 These observations were consistent with 
mathematical models that predicted better out-
comes with block-sequential therapy7,8 than with 
an alternating regimen of non–cross-resistant 
agents.9,10
For these reasons, we adopted a block-sequen-
tial schedule for the anthracycline-containing regi-
mens used in NEAT and the BR9601 trial, with 
three modifications. First, we used epirubicin 
instead of doxorubicin to reduce treatment-related 
adverse effects.11 Second, in NEAT, we adminis-
tered classic CMF (see the glossary for chemother-
apy schedules)12 because of its superior efficacy 
in metastatic breast cancer13 and the importance 
of dose delivery of CMF in early breast cancer.14 
In the BR9601 trial, the classic CMF regimen was 
modified, with all three drugs given intravenous-
ly once every 3 weeks, to minimize the need for 
patients to travel to a specialized center in Scot-
land, since this is an area of low population den-
sity and a large proportion of enrollees did not live 
close to such a center. Third, we shortened the 
duration of therapy by cutting the sequentially 
administered CMF to four cycles in the anthracy-
Glossary of Chemotherapy Schedules.
Classic CMF: Six cycles of cyclophosphamide (100 mg per square meter of body-surface area given orally every day for 
14 days or, at the clinician’s preference, 600 mg per square meter given intravenously on days 1 and 8) with metho-
trexate (40 mg per square meter) and fluorouracil (600 mg per square meter) given intravenously on days 1 and 
8 of the cycle.
Modified CMF in the BR9601 trial: Eight cycles of cyclophosphamide (750 mg per square meter), methotrexate (50 mg 
per square meter), and fluorouracil (600 mg per square meter), all given intravenously on day 1 every 3 weeks.
Epirubicin plus CMF in NEAT: Four cycles of epirubicin (100 mg per square meter) every 3 weeks, followed by four cy-
cles of classic CMF.
Epirubicin plus CMF in the BR9601 trial: Four cycles of epirubicin (100 mg per square meter) every 3 weeks, followed 
by four cycles of the modified CMF schedule.
FEC100: Fluorouracil (500 mg per square meter), epirubicin (100 mg per square meter), and cyclophosphamide 
(500 mg per square meter), all given intravenously every 3 weeks.
FEC50: Fluorouracil (500 mg per square meter), epirubicin (50 mg per square meter), and cyclophosphamide (500 mg 
per square meter), all given intravenously every 3 weeks.
CEF: Cyclophosphamide (75 mg per square meter), given orally every day for 14 days; epirubicin (60 mg per square me-
ter) and fluorouracil (500 mg per square meter), both given intravenously on days 1 and 8 every 4 weeks for six 
cycles (with routine antibiotic prophylaxis).
Doxorubicin plus CMF: Doxorubicin (75 mg per square meter) given every 3 weeks for four cycles, followed by four 
cycles of classic CMF.
Doxorubicin and paclitaxel plus CMF: Doxorubicin (60 mg per square meter) and paclitaxel (200 mg per square meter), 
both given intravenously every 3 weeks for four cycles, followed by intravenous cyclophosphamide (600 mg per 
square meter), methotrexate (40 mg per square meter), and fluorouracil (600 mg per square meter) on days 1 and 
8 every 4 weeks for four cycles.
FEC plus docetaxel: Fluorouracil (600 mg per square meter), epirubicin (60 mg per square meter), and cyclophospha-
mide (600 mg per square meter), all given intravenously every 3 weeks for four cycles, followed by docetaxel (100 
mg per square meter) given intravenously every 3 weeks for four cycles (with routine antibiotic prophylaxis).
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cline groups of both trials. The control treatments 
in each trial were of equal duration, with six cy-
cles of classic CMF in NEAT and eight cycles of the 
CMF schedule in the BR9601 trial.
METHODS
Study Design
We designed both phase 3 trials to test the hypoth-
esis that, as compared with CMF alone, four cy-
cles of epirubicin plus four cycles of CMF would 
improve overall and relapse-free survival among 
women with early breast cancer. A parallel study 
design was used to maximize recruitment north 
and south of the border between England and Scot-
land, with NEAT predominantly recruiting wom-
en from the United Kingdom and the BR9601 trial 
predominantly recruiting women from Scotland 
(see the Supplementary Appendix, available with 
the full text of this article at www.nejm.org). The 
trials were coordinated in parallel, with a joint 
analysis of outcomes from a single amalgamated 
data set, planned at the outset and facilitated by 
similar approaches to stratification and data col-
lection (Fig. 1). Both trials were approved by a mul-
ticenter research ethics committee and by the lo-
cal research ethics committee at each participating 
hospital. Pharmacia did not participate in the study 
design, data collection or analysis, or preparation 
of the manuscript.
Patients
Women with completely excised early breast can-
cer who required adjuvant chemotherapy and could 
start treatment within 10 weeks after surgery were 
eligible for the study. Additional eligibility criteria 
were adequate renal, hepatic, and bone marrow 
function; the absence of previous exposure to che-
motherapy or radiotherapy; the absence of previ-
ous or concomitant cancer; and provision of writ-
ten informed consent.
Treatment
In each trial, patients were assigned to epirubicin 
plus CMF or CMF alone with the use of a permuted-
block, 1:1 randomization scheme (Fig. 1). Treat-
ment assignments were made by telephone to cen-
tral locations. Both NEAT and the BR9601 trial 
stratified patients according to center, age, and 
nodal status; NEAT also stratified patients accord-
ing to planned radiotherapy schedule. NEAT used 
epirubicin plus CMF for the anthracycline group 
and classic CMF alone for the control group (see 
the Glossary). BR9601 used epirubicin plus the 
modified CMF regimen for the anthracycline group 
and the modified CMF regimen alone for the con-
trol group (see the Glossary). Neither trial restrict-
ed adjuvant hormonal treatment. Of the 1458 
patients in NEAT for whom data were available 
regarding clinicians’ proposals for adjuvant tamox-
ifen, 68% were to receive adjuvant tamoxifen, and 
32% were not. Scheduling information was avail-
able for 843 of these patients (452 in the epirubi-
cin–CMF group and 391 in the CMF group); 46% 
were to receive tamoxifen concurrently with che-
motherapy (48% of those in the epirubicin–CMF 
group and 45% of those in the CMF group), and 
54% were to receive tamoxifen after chemothera-
py (52% of those in the epirubicin–CMF group and 
55% of those in the CMF group).
Statistical Analysis
A combined enrollment of 2000 patients was re-
quired for the study to have a statistical power of 
85% to detect an absolute difference of 7% in both 
overall and relapse-free survival between the treat-
ment groups, with a 5% (two-sided) level of sig-
nificance. However, in NEAT, the goal was to en-
roll 2000 patients independently in order to allow 
an unbiased analysis of the specified treatment 
regimens. In the BR9601 trial, the goal was to en-
roll an additional 300 to 500 patients in order to 
increase the statistical power of the comparison 
between epirubicin plus CMF and CMF alone in 
a planned joint analysis.
Relapse-free and Overall Survival
The primary outcome measures were relapse-free 
and overall survival. Relapse-free survival was cal-
culated from the date of surgery to the date of a 
first relapse, to the date of death without relapse, 
or to the date of data censoring (for women who 
remained alive and relapse-free). Overall survival 
was calculated from the date of surgery to the date 
of death or to the date of data censoring (for wom-
en who remained alive). Survival curves were con-
structed with the use of Kaplan–Meier methods.15 
We used log-rank tests to compare patient and tu-
mor characteristics and treatments. Cox propor-
tional-hazards models16 were constructed to eval-
uate and make adjustments for prognostic factors. 
We calculated hazard ratios for relapse (and death 
without relapse) and death from any cause in prog-
nostic subgroups, and constructed forest plots.17 
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Secondary outcome measures were adverse effects, 
dose intensity, and for a subgroup of NEAT pa-
tients, the quality of life.
Adverse Effects
Common Toxicity Criteria (CTC) grades were re-
corded for each cycle of chemotherapy. We used 
chi-square tests with Bonferroni corrections for 
multiple comparisons to compare the treatment 
groups with respect to the number of patients with 
severe adverse effects (defined as a CTC grade ≥3, 
or grade 2 for alopecia).
Dose Intensity
The Supplementary Appendix describes the calcu-
lation of the course-delivered dose intensity. The 
treatment groups were compared with respect to 
the dose intensity of delivered doses in each cycle 
and of the full course of chemotherapy with the 
use of Wilcoxon rank-sum tests and chi-square 
tests with continuity corrections.
Quality of Life
The European Organisation for Research and Treat-
ment of Cancer questionnaire for assessing the 
health-related quality of life of patients with can-
cer (QLQ-C30),18 their supplementary breast can-
cer module (QLQ-BR23),19 and the Women’s Health 
Questionnaire20 were administered at randomiza-
tion, midway through chemotherapy, at the end of 
chemotherapy, and 1 and 2 years after random-
ization. A standardized area-under-the-curve anal-
NEAT BR9601
Combined Total
2401 Underwent randomization
1194 Assigned to epirubicin
plus CMF
1189 Included in analysis
5 Ineligible (previous tumor
 or existing metastases) 
1182 Received randomized treat-
ment
7 Protocol violations
6 Patients received treatment  
in other group
1 Patient declined treatment 
after cycle 5
No patients lost to follow-up
1207  Assigned to CMF
1202 Included in analysis
5 Ineligible (previous tumor
 or existing metastases) 
1194 Received randomized treat-
ment
8 Protocol violations
2 Patients chose to discon-
tinue treatment 
3 Administration errors
3 Patients withdrew consent
No patients lost to follow-up
2027 Patients underwent randomization
1011 Assigned to epirubicin
plus classic CMF
1016 Assigned to classic
CMF
374 Patients underwent randomization
183 Assigned to epirubicin
plus modified CMF
191 Assigned to modified
CMF
Figure 1. Enrollment, Randomization, Receipt of Study Treatment, and Follow-up in the Two Trials.
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ysis21 was carried out for the quality of life during 
the treatment period, and changes from baseline 
to 1 year and from baseline to 2 years were calcu-
lated to assess long-term effects. Treatments were 
compared with the use of O’Brien’s global rank 
procedure22 and Wilcoxon rank-sum tests. Scores 
were on a scale of 0 to 100, with higher scores rep-
resenting better quality of life (either higher func-
tional scores, lower symptom levels, or higher 
quality-of-life scores). Negative changes over time 
thus represented a decline in quality of life, and 
positive changes represented an improvement in 
quality of life. 
The joint analysis of the two trials was under-
taken by the Cancer Research U.K. Clinical Trials 
Unit, Birmingham, with the use of SAS software. 
Results from the first preplanned, event-driven, 
analysis of the primary end points for both trials 
are presented. Given 400 end-point events, the 
study would have a statistical power of 99% to 
detect an absolute difference of 10% between treat-
ment groups with a 5% (two-sided) level of sig-
nificance. The results for trial-specific adverse 
events, course-delivered dose intensity, and the 
quality of life are summarized here. All reported 
P values are two-sided. Data for all patients whose 
treatment involved protocol violations were ana-
lyzed within the groups to which the patients had 
been randomly assigned, an approach that allowed 
us to perform the analysis on an intention-to-treat 
basis.
Results
Patients
NEAT recruited 2027 patients from 111 clinicians 
at 65 centers between April 1996 and July 2001. 
The BR9601 trial began in October 1996 and closed 
in April 2001 after recruiting 374 patients from 26 
clinicians at 10 centers. Ten patients were ineligi-
ble for the trial: 6 in NEAT (2 patients who received 
epirubicin plus CMF and 4 who received CMF 
alone) and 4 patients in BR9601 (3 patients who 
received epirubicin plus CMF and 1 patient who 
received CMF alone), principally because of meta-
static breast cancer or a history of other cancer, 
leaving 2391 eligible patients for analysis (Fig. 1).
Patients’ characteristics, the type of operation, 
the timing of surgery (Table 1), and tumor char-
acteristics (Table 3 of the Supplementary Appen-
dix) were similar among the treatment groups. The 
clinically significant differences between the two 
trials included more women under the age of 50 
years and more node-negative tumors in NEAT and 
larger tumors and more frequent mastectomies in 
the BR9601 trial.
Treatment Compliance
Violations of the assigned protocol were noted by 
the trial management groups in the treatment of 
15 patients: 12 in NEAT (7 assigned to receive epi-
rubicin plus CMF, and 5 assigned to receive CMF 
alone) and 3 in the BR9601 trial (all assigned to 
receive CMF alone). All analyses included these pa-
tients in their assigned groups, according to the 
intention-to-treat principle.
Overall and Relapse-Free Survival
After a median follow-up of 48 months, 413 wom-
en had died (17% of all 2391 eligible women, 16% 
of those in NEAT, and 23% of those in the BR9601 
trial) (Table 4 of the Supplementary Appendix). The 
median time to death was 2.5 years (range, 45 days 
to 7 years). The main cause of death was breast 
cancer (in 92% of the women who died). Locore-
gional or distant relapse was reported in 491 wom-
en, with distant metastases predominantly in the 
bone, liver, or both. There were 545 events in the 
analysis of relapse-free survival. Follow-up was 
equivalent between trials and treatments (medi-
an, 48 months; range, 6 months to 7.5 years) and is 
continuing.
Figure 2 compares survival curves for the groups 
that received epirubicin plus CMF and the groups 
that received CMF alone. The rate of overall sur-
vival at 2 years was 95% in the epirubicin plus 
CMF group and 92% in the CMF group. The sur-
vival rate at 5 years was 82% in the epirubicin plus 
CMF group and 75% in the CMF group (P<0.001 
by the log-rank test) (Fig. 2A). The hazard ratio for 
death from any cause in the epirubicin plus CMF 
group, as compared with the CMF group, was 
0.67 (95% confidence interval [CI], 0.55 to 0.82; 
P<0.001). The rate of relapse-free survival at 2 years 
was 91% in the epirubicin plus CMF group and 
85% in the CMF group. At 5 years, the rate of re-
lapse-free survival was 76% in the epirubicin plus 
CMF group and 69% in the CMF group (P<0.001 
by the log-rank test) (Fig. 2B). The hazard ratio for 
relapse (or death without relapse) in the epirubi-
cin plus CMF group, as compared with the CMF 
group, was 0.69 (95% CI, 0.58 to 0.82; P<0.001). 
The results for overall survival and relapse-free 
survival in NEAT were similar to those in the 
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BR9601 trial (P = 0.39 for overall survival and 
P = 0.34 for relapse-free survival) (Fig. 5 of the Sup-
plementary Appendix).
Univariate analysis showed that the following 
factors were significantly associated with relapse-
free survival: treatment (epirubicin plus CMF or 
CMF alone), nodal status (no positive nodes, 1 to 
3 positive nodes, or ≥4 positive nodes), estrogen-
receptor status (positive, negative, or unknown), 
tumor size (≤2 cm or >2 cm) and grade (1, 2, or 
3), vascular or lymphatic invasion (reported or un-
reported), and type of surgery (mastectomy or 
breast-conserving surgery) (P<0.001 for all com-
parisons) (Table 2). All these factors except the 
type of surgery were independently associated with 
relapse-free survival in a multivariate analysis (Ta-
ble 6 of the Supplementary Appendix). A base 
model of these factors confirmed that treatment 
was an independent prognostic factor for relapse-
free survival (P<0.001). The ranking of these fac-
tors was as follows: nodal status, tumor grade, 
tumor size, treatment, estrogen-receptor status, 
and presence or absence of vascular or lymphatic 
invasion. The results were similar for overall sur-
vival, with the exception that vascular or lymphatic 
invasion was not a prognostic factor.
Interaction of Treatment Effect 
with Prognostic Factors
Forest plots showed similar effects of treatment 
on relapse-free survival, regardless of nodal status, 
estrogen-receptor status, tumor diameter, tumor 
grade, age, menopausal status, performance status, 
surgery, and presence or absence of vascular or 
lymphatic invasion (Fig. 5 of the Supplementary 
Appendix). The results of all statistical tests of het-
erogeneity were nonsignificant. Similar results 
were obtained for overall survival.
adverse effects of Chemotherapy
Complete information regarding adverse effects 
was available for 1952 of 2021 patients (97%) in 
NEAT and 366 of 370 patients (99%) in the BR9601 
trial. In NEAT, significantly more patients in the 
epirubicin plus CMF group than in the CMF group 
reported severe alopecia (84% vs. 27%), nausea 
(15% vs. 7%), vomiting (12% vs. 4%), constipation 
(6% vs. 2%), and stomatitis (6% vs. 3%) (Table 3). 
In NEAT, the treatment groups did not differ sig-
nificantly with respect to the proportions of 
patients reporting severe diarrhea (6% in both 
groups), infection (7% in the epirubicin plus CMF 
group and 5% in the CMF group), fatigue (21% 
and 18%, respectively), neutropenia (15% in both 
groups), or thrombocytopenia (1% in both groups). 
Neutropenic sepsis (neutropenia and infection in 
the same cycle) was recorded in 346 cycles (3% in 
each group) and by 247 patients (13%): 14% of 
those in the epirubicin plus CMF group and 11% 
of those in the CMF group.
In the BR9601 trial, the proportion of patients 
who reported severe alopecia was significantly 
higher in the epirubicin plus CMF group than in 
the CMF group (96% vs. 76%). However, the two 
groups did not differ significantly with respect to 
the proportions of patients who reported severe 
nausea (16% in the epirubicin plus CMF group and 
11% in the CMF group), vomiting (12% and 9%, 
respectively), stomatitis (4% and 3%), diarrhea (3% 
in both groups), infection (5% and 2%), or fatigue 
(25% and 17%).
Of premenopausal patients for whom data 
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Figure 2. Kaplan–Meier Estimates of Overall Survival (Panel A) and Re-
lapse-free Survival (Panel B) According to Treatment.
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were available, 73% reported chemotherapy-related 
amenorrhea. The rates were similar in the two tri-
als and in the treatment groups (in NEAT, 71% for 
epirubicin plus CMF and 74% for CMF alone; in 
the BR9601 trial, 73% for epirubicin plus CMF and 
74% for CMF alone).
Table 2. Relapse-free Survival According to Treatment, Tumor, and Patient Characteristics.
Variable
No. of 
Patients*
No. of 
Events P Value Relapse-free Survival 
2 Yr 5 Yr
% (95% CI)
Overall 2391 545 88 (87–90) 73 (71–75)
Treatment <0.001
Epirubicin plus CMF 1189 230 91 (89–93) 76 (73–79)
CMF 1202 315 85 (83–87) 69 (66–72)
No. of nodes involved <0.001
0 673 90 92 (90–94) 84 (80–87)
1–3 1129 219 91 (89–93) 76 (73–80)
≥4 589 236 79 (76–82) 55 (50–60)
Estrogen-receptor status <0.001
Positive 1187 211 92 (91–94) 77 (74–80)
Negative 761 196 84 (81–86) 69 (65–73)
Unknown 443 138 85 (82–88) 68 (63–73)
Tumor size <0.001
≤2 cm 1021 173 92 (90–94) 79 (76–82)
>2 cm 1313 354 85 (83–87) 68 (65–71)
Tumor grade <0.001
1 151 17 96 (93–99) 87 (80–93)
2 809 151 91 (90–93) 76 (72–80)
3 1394 371 85 (84–87) 69 (66–72)
Vascular or lymphatic invasion <0.001
Reported 1220 340 86 (84–88) 67 (64–70)
Unreported 1171 205 91 (89–92) 79 (76–82)
Surgery <0.001
Mastectomy 1249 333 86 (84–87) 69 (65–72)
Breast-conserving surgery 1132 210 91 (89–93) 77 (74–80)
Menopausal status 0.06
Premenopausal or perimenopausal 1354 308 90 (88–91) 73 (70–76)
Postmenopausal 911 221 85 (83–88) 71 (68–75)
Age 0.21
≤50 yr 1412 317 89 (87–91) 73 (70–76)
>50 yr 979 228 87 (85–89) 72 (68–75)
Performance status 0.55
0 1671 368 89 (87–90) 73 (70–76)
1 or 2 419 106 87 (84–90) 71 (66–76)
Unknown 301 71 87 (83–91) 72 (66–78)
* Patients with missing data for a given variable were excluded from the analysis of that variable.
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Deaths Attributed to Chemotherapy
Among the 2391 patients, 20 deaths were attributed 
to treatment-related adverse effects (1%), with a 
similar incidence in the two trials. Of these 20 
deaths, 18 occurred in patients in NEAT (5 patients 
who received epirubicin plus CMF and 13 who re-
ceived CMF alone). Eight of the 18 deaths were due 
to neutropenic sepsis (in 4 patients who received 
epirubicin plus CMF and 4 who received CMF 
alone), 5 to pulmonary emboli (in 1 patient who 
received epirubicin plus CMF and 4 patients who 
received CMF alone), and 4 to cerebrovascular ac-
cidents (all in patients who received CMF alone); 
autopsy failed to elucidate a cause of death in 
1 patient who received CMF alone and who had 
a normal blood count at the time of death. Two 
patients died of treatment-related adverse effects 
in the BR9601 trial: one patient who received epi-
rubicin plus CMF died of cholecystitis, and one pa-
tient who received CMF alone died of bronchopneu-
monia. In all four treatment groups in the two 
trials, all deaths from treatment-related adverse ef-
fects occurred during treatment with CMF. Among 
patients who received CMF, deaths due to treat-
ment-related adverse effects occurred in all treat-
ment cycles.
Delivered Dose Intensity
The excess incidence of treatment-related adverse 
effects among patients who received epirubicin 
plus CMF did not compromise the course-deliv-
ered dose intensity in either trial, in terms of either 
the median overall delivered-dose intensity or the 
proportion of patients receiving an adequate dose 
intensity (≥85% of planned doses). (See the Supple-
mentary Appendix for additional information.)
Quality of Life
The 511 patients in NEAT who were included in 
the quality-of-life analysis were representative of 
the overall study population in NEAT in terms of 
baseline characteristics, overall survival, and re-
lapse-free survival. During treatment, patients who 
received epirubicin plus classic CMF reported sig-
nificantly more severe symptoms than did those 
who received classic CMF alone, as measured by 
the QLQ-BR23 questionnaire (P = 0.05). An analysis 
of the relevant QLQ-BR23 symptom subscales 
identified significantly worse scores for patients 
who received epirubicin plus CMF than for patients 
who received CMF alone. These scores included 
“systemic therapy side effects” (median, 69 [in-
terquartile range, 57 to 77] and 72 [interquartile 
range, 63 to 82], respectively; P<0.01) and “upset 
by hair loss” (median, 33 [interquartile range, 0 to 
67] and 67 [interquartile range, 33 to 87], respec-
tively; P<0.01). There were no other significant 
differences in the quality of life between the two 
groups during treatment. However, an analysis of 
changes from baseline to 1 year showed that pa-
Table 3. Severe Adverse Effects.*
Adverse Effect NEAT BR9601
Epirubicin plus
Classic CMF
(N = 979)
Classic CMF 
(N = 973)
Epirubicin plus 
Modified CMF 
(N = 178)
Modified CMF 
(N = 188)
number of patients (percent)
Alopecia 820 (84)† 263 (27) 171 (96)† 142 (76)
Nausea 146 (15)† 69 (7) 28 (16) 20 (11)
Vomiting 113 (12)† 36 (4) 22 (12) 16 (9)
Constipation 62 (6)† 24 (2) NR NR
Stomatitis 61 (6)‡ 27 (3) 7 (4) 5 (3)
Diarrhea 56 (6) 58 (6) 6 (3) 6 (3)
Infection 64 (7) 51 (5) 9 (5) 4 (2)
Fatigue 204 (21) 177 (18) 45 (25) 32 (17)
Neutropenia 151 (15) 143 (15) NR NR
Thrombocytopenia 8 (1) 10 (1) NR NR
* Severe adverse effects were defined as those with a CTC grade of 3 or higher, except for alopecia, which was defined as 
a grade of 2 or higher. NR denotes specific adverse effect not recorded.
† P<0.001 for the comparison with CMF.
‡ P = 0.002 for the comparison with CMF.
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tients who received CMF alone had less improve-
ment in global health and a greater increase in 
symptoms, as measured by the QLQ-C30 ques-
tionnaire (P = 0.01). The median change in global 
quality of life was 8.3 (interquartile range, 0 to 
16.7) for patients who received epirubicin plus 
CMF and 0 (interquartile range, −8.3 to 16.7) for 
patients who received CMF alone. In addition, an 
analysis of the relevant symptom subscales showed 
that patients who received CMF alone had more 
dyspnea at 1 year than at baseline (median change, 
0 [interquartile range, −33 to 0]) than patients 
who received epirubicin plus CMF (median change, 
0 [interquartile range, 0 to 0]; P = 0.04). An analy-
sis of changes from baseline to 2 years showed 
no significant differences in the quality of life be-
tween the two groups.
Discussion
Our combined analysis of NEAT and the BR9601 
trial, at a median follow-up of 48 months, shows 
the superiority of epirubicin plus CMF over CMF 
alone for the treatment of early breast cancer. The 
hazard ratios for relapse (or death without relapse) 
(0.69) and for death from any cause (0.67) were 
significant (P<0.001 for both comparisons), and 
these findings were unlikely to be due to an arti-
fact of the slight difference between the duration 
of treatment in the research and control groups 
of the NEAT trial. Furthermore, the results were 
similar in the two trials, despite the differences in 
treatments. We can therefore attribute the advan-
tage of epirubicin plus CMF to the epirubicin com-
ponent of the combination chemotherapy.
The results of this analysis are applicable to 
most patients with breast cancer. There were no 
significant influences of estrogen-receptor status 
(P = 0.17 by a test for heterogeneity) or tumor grade 
(P = 0.34 by a test for trend), and even though the 
proportion of women younger than 50 years of age 
was larger in the population we studied than that 
in the general population of women with breast 
cancer, we can discern no loss of efficacy among 
older women (P = 0.50) (Fig. 5 of the Supplemen-
tary Appendix).
Severe effects were reported in less than 5% of 
cycles. As anticipated, there were moderate differ-
ences in the incidence of treatment-related adverse 
effects, with higher rates with epirubicin plus CMF 
than with CMF alone and a short-term reduction 
in the quality of life during chemotherapy. How-
ever, the majority of treatment-related deaths oc-
curred in the CMF group (14, vs. 6 in the epi-
rubicin plus CMF group), and all 6 deaths in the 
epirubicin plus CMF group occurred during the 
CMF phase of therapy.
In the Early Breast Cancer/Mammary5 (EBC-1/
MA.5) study by the National Cancer Institute of 
Canada Clinical Trials Group (NCIC CTG), which 
compared a combination of cyclophosphamide, 
epirubicin, and fluorouracil (CEF) with CMF alone 
in premenopausal women with node-positive breast 
cancer,23 the rate of relapse-free survival at 5 years 
was 53% in the CMF group and 63% in the CEF 
group (P = 0.009); the rate of overall survival at 
5 years was 70% and 77%, respectively (P = 0.03). 
Patients did not receive adjuvant tamoxifen in 
EBC-1/MA.5. The delivered dose intensity of CEF 
was 80 to 83%, as compared with 96% for CMF, 
suggesting that six cycles of CEF, with a total dose 
of epirubicin of 120 mg per square meter per 
4-week cycle, may be a less tolerable regimen than 
epirubicin plus CMF (Table 7 of the Supplemen-
tary Appendix). 
On the basis of the data from NEAT and the 
BR9601, and NCIC CTG trial, as well as data from 
the French Adjuvant Study Group’s Early Breast 
Cancer 05 trial,24 which showed an advantage of 
FEC100 over FEC50, it is plausible that adequate 
doses of epirubicin, in the range of 100 to 120 mg 
per square meter per cycle, provide more benefit 
than was found in a meta-analysis of the substitu-
tion of an anthracycline for methotrexate conduct-
ed by the Early Breast Cancer Trialists Collabora-
tive Group.25 The International Collaborative Cancer 
Group study,26 which compared FEC50 with clas-
sic CMF, did not show that the substitution of 
epirubicin (at a dose of 50 mg per square meter) 
for methotrexate produced significantly better re-
sults.
Analysis of the data from the NCIC CTG stud-
ies27 has shown a cumulative incidence of second-
ary leukemia of 2% at 8 years’ follow-up among 
women treated with epirubicin-based adjuvant che-
motherapy. The follow-up in NEAT and the BR9601 
trial (48 months) is too short to assess the inci-
dence of secondary acute myeloid leukemia, which 
typically occurs 2 to 4 years after anthracycline 
treatment.28 We found only one case — an acute 
promyelocytic leukemia. Although this is not the 
typical subtype of acute myeloid leukemia attrib-
uted to anthracyclines, an association between 
promyelocytic leukemia and exposure to a topoi-
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somerase II inhibitor has been described.29,30 We 
do not anticipate many late cases of acute my-
eloid leukemia because the low cumulative dose of 
epirubicin in our trials reduces the risk of anthra-
cycline-related acute myeloid leukemia.28
Block-sequential designs of single-agent anthra-
cycline therapy followed by CMF have been used 
in the control groups of a number of important 
phase 3 clinical trials. These trials include the 
Anglo-Celtic trial,31 which showed no benefit of 
high-dose chemotherapy, and the European Co-
operative Trial in Operable Breast Cancer (ECTO),32 
which showed that doxorubicin and paclitaxel plus 
CMF was superior with respect to relapse-free sur-
vival to doxorubicin plus CMF. On the basis of the 
NEAT and BR9601 efficacy data, of all the taxane-
containing anthracycline-based regimens that have 
been evaluated, doxorubicin and paclitaxel plus 
CMF may come closest to fully exploiting the po-
tential of these drugs. Epirubicin plus CMF (in the 
same doses used in NEAT) has been used in an 
optional control group in a study in the United 
Kingdom, the Taxotere as Adjuvant Chemotherapy 
Trial (TACT)33 (as compared with FEC and docetax-
el), and in the ongoing TACT2 (as compared with 
epirubicin plus capecitabine) in a bifactorial de-
sign also evaluating dose-dense epirubicin. Anal-
ysis of the role that amplification of the human 
epidermal growth factor receptor type 2 gene 
(HER2) and the topoisomerase IIα gene (TOP2A) 
plays in determining anthracycline sensitivity in 
the NEAT and BR9601 treatment populations is 
ongoing. At this point, there are no reported data 
on the safety or efficacy of trastuzumab when 
used concurrently with epirubicin plus CMF, al-
though trastuzumab has been given as mainte-
nance therapy after adjuvant treatment with epi-
rubicin plus CMF in women with HER2-positive 
early breast cancer.34 Buzdar et al. reported that 
there were no cases of congestive cardiac failure 
in their trial, in which 44 patients were randomly 
assigned to neoadjuvant treatment with paclitax-
el, followed by four cycles of the FEC regimen 
with or without herceptin administered concur-
rently for 24 weeks. However, they acknowledge 
that their study was too small for conclusions to 
be drawn about the safety of this approach.35
In conclusion, adjuvant treatment of early breast 
cancer with epirubicin plus CMF has significant 
superiority over CMF alone in terms of relapse-
free survival and overall survival. Although there 
was a higher incidence of treatment-related adverse 
effects with epirubicin plus CMF, its use was as-
sociated with adverse effects on the quality of life 
that are similar to those associated with CMF 
treatment. On the basis of the results in 75 cen-
ters, we recommend epirubicin plus CMF as an 
option for anthracycline-based adjuvant chemo-
therapy in women with early breast cancer.
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